Breaking News

BIOPHYTIS Selects SGS for MACA-PK Clinical Study

Study will assess the safety, pharmacokinetics and pharmacodynamics of Macuneos in AMD

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BIOPHYTIS has contracted SGS Life Science Services to conduct the MACA-PK clinical study of its drug candidate Macuneos for the treatment of age-related macular degeneration (AMD). The objective of MACA-PK is to study the safety, pharmacokinetics and pharmacodynamics of Macuneos. The MACA-PK study is a Phase I/IIa study, whose protocol has been optimized to study the safety, pharmacokinetics and pharmacodynamics of Macuneos in healthy volunteers in a Belgian clinical center in 2017, and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters